1
|
Betancor D, Otal M, Olaguibel JM, Rodrigo-Muñoz JM, Alvarez Puebla JM, Arismendi E, Barranco P, Barroso B, Bobolea I, Cárdaba B, Cruz MJ, Curto E, Del Pozo V, Domínguez-Ortega J, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Picado C, Plaza V, Quirce S, Rial MJ, Roibás-Veiga I, Soto-Retes L, Valero A, Valverde-Monge M, Sastre J. Global Lung Initiative as diagnostic criteria in Asthma-COPD overlap syndrome. Prevalence and characterization of the syndrome in a real-life asthma cohort. J Investig Allergol Clin Immunol 2023; 34:0. [PMID: 38131661 DOI: 10.18176/jiaci.0966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023] Open
Affiliation(s)
- D Betancor
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M Otal
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J M Olaguibel
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J M Rodrigo-Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria del Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J M Alvarez Puebla
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic; Universitat de Barcelona, Barcelona, Spain
| | - P Barranco
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, Madrid, Spain
| | - B Barroso
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Bobolea
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic; Universitat de Barcelona, Barcelona, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria del Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - E Curto
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria del Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J Domínguez-Ortega
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, Madrid, Spain
| | - F J González-Barcala
- Department of Respiratory Medicine, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
| | - J A Luna-Porta
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, Madrid, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Neumología, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Rhinology Unit & Smell Clinic, ENT Department; Universitat de Barcelona. Barcelona, Spain
| | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Neumología, Hospital Vall d'Hebron, Barcelona, Spain
| | - C Picado
- Pneumonology and Allergy Department, Hospital Clínic; Universitat de Barcelona, Barcelona, Spain
| | - V Plaza
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - S Quirce
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, Madrid, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergología, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - I Roibás-Veiga
- Servicio de Alergia. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - L Soto-Retes
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic; Universitat de Barcelona, Barcelona, Spain
| | - M Valverde-Monge
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J Sastre
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
2
|
Bantulà M, Tubita V, Roca-Ferrer J, Mullol J, Valero A, Bobolea I, Pascal M, de Hollanda A, Vidal J, Picado C, Arismendi E. Weight Loss and Vitamin D Improve Hyporesponsiveness to Corticosteroids in Obese Asthma. J Investig Allergol Clin Immunol 2023; 33:464-473. [PMID: 36098275 DOI: 10.18176/jiaci.0861] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Obesity negatively impacts on the response of asthma patients to inhaled corticosteroids. The mechanisms underlying this impact are unknown. Objective: To demonstrate that the poor response to inhaled corticosteroids in obese asthma patients is associated with impaired anti-inflammatory activity of corticosteroids and vitamin D deficiency, both of which are improved by weight loss. METHODS The study population comprised 23 obese asthma patients (OA) (18 females; median (IQR) age 56 [51-59] years), 14 nonobese asthma patients (NOA) (11 females; 53 [43-60] years), 15 obese patients (OP) (13 females; 47 [45-60] years), and 19 healthy controls (HC) (14 females; 43 [34-56] years). Ten OA and 11 OP were evaluated at baseline (V1) and 6 months after bariatric surgery (V2). Corticosteroid response was measured using dexamethasone-induced inhibition of peripheral blood mononuclear cell (PBMC) proliferation. Lung function and serum levels of leptin, adiponectin, and vitamin D were measured at V1 and V2. RESULTS We found a reduced response to dexamethasone in PBMCs of OP and OA with respect to NOA and HC; this inversely correlated with the adiponectin/leptin ratio and vitamin D levels. Bariatric surgery improved corticosteroid responses in OP and OA and normalized the adiponectin/leptin ratio and vitamin D levels. Exposure of PBMCs to vitamin D potentiated the antiproliferative effects of corticosteroids. Dexamethasone and vitamin D induced similar MKP1 expression in OP and OA. CONCLUSION The efficacy of weight loss to improve symptoms and lung function in OA may be due, at least in part, to the recovered anti-inflammatory effects of corticosteroids. Vitamin D deficiency may contribute to corticosteroid hyporesponsiveness in OA.
Collapse
Affiliation(s)
- M Bantulà
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - V Tubita
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - J Roca-Ferrer
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J Mullol
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain
| | - A Valero
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital Clinic, Barcelona, Spain
| | - I Bobolea
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital Clinic, Barcelona, Spain
| | - M Pascal
- Immunology Department, Hospital Clinic, Barcelona, Spain
| | - A de Hollanda
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Obesity Unit, Endocrinology and Nutrition Department, Hospital Clínic, Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Fisopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain
| | - J Vidal
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Obesity Unit, Endocrinology and Nutrition Department, Hospital Clínic, Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red en Diabetes y Enfermedades Metabólicas (CIBERDEM), Madrid, Spain
| | - C Picado
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital Clinic, Barcelona, Spain
| | - E Arismendi
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital Clinic, Barcelona, Spain
| |
Collapse
|
3
|
Barroso B, Valverde-Monge M, Alobid I, Olaguibel JM, Rial MJ, Quirce S, Arismendi E, Barranco P, Betancor D, Bobolea I, Cárdaba B, Cruz Carmona MJ, Curto E, Domínguez-Ortega J, González-Barcala FJ, Martínez-Rivera C, Mahíllo-Fernández I, Muñoz X, Picado C, Plaza V, Rodrigo Muñoz JM, Soto-Retes L, Valero A, Del Pozo V, Mullol J, Sastre J. Reply to "Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies". J Investig Allergol Clin Immunol 2023; 33:503-504. [PMID: 38095497 DOI: 10.18176/jiaci.0953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2023] Open
Affiliation(s)
- B Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - M Valverde-Monge
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Alobid
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
| | - J M Olaguibel
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Allergy Department, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Allergy Department, Hospital Juan Canalejo, A Coruña, Spain
| | - S Quirce
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - P Barranco
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - D Betancor
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Bobolea
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz Carmona
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - E Curto
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J Domínguez-Ortega
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - F J González-Barcala
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology Department, Hospital Germans Trias i Pujol, Badalona, Spain
| | | | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - C Picado
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Plaza
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J M Rodrigo Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - L Soto-Retes
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
| | - J Sastre
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
4
|
Betancor D, Olaguibel JM, Rodrigo-Muñoz JM, Alvarez Puebla MJ, Arismendi E, Barranco P, Barroso B, Bobolea I, Cárdaba B, Cruz MJ, Curto E, Del Pozo V, Domínguez-Ortega J, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Picado C, Plaza V, Quirce S, Rial MJ, Soto-Retes L, Valero A, Valverde-Monge M, Sastre J. Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma. J Investig Allergol Clin Immunol 2023; 33:294-296. [PMID: 36331127 DOI: 10.18176/jiaci.0866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/28/2023] Open
Affiliation(s)
- D Betancor
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J M Olaguibel
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J M Rodrigo-Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Alvarez Puebla
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Universitat de Barcelona. Barcelona, Spain
| | - P Barranco
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - B Barroso
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - I Bobolea
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Universitat de Barcelona. Barcelona, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - E Curto
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J Domínguez-Ortega
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - F J González-Barcala
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - J A Luna-Porta
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Neumología, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Universitat de Barcelona. Barcelona, Spain
- Rhinology Unit and Smell Clinic, ENT Department Hospital Clínic, Barcelona, Spain
| | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Neumología, Hospital Vall d'Hebron, Barcelona, Spain
| | - C Picado
- Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Plaza
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - S Quirce
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergología, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - L Soto-Retes
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - M Valverde-Monge
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J Sastre
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
5
|
Domínguez-Ortega J, Luna-Porta JA, Olaguibel JM, Barranco P, Arismendi E, Barroso B, Betancor D, Bobolea I, Caballero ML, Cárdaba B, Cruz MJ, Curto E, González-Barcala FJ, Losantos-García I, Martínez-Rivera C, Mendez-Brea P, Mullol J, Muñoz X, Picado C, Plaza V, Del Pozo V, Rial MJ, Sastre J, Soto L, Valero A, Valverde-Monge M, Quirce S. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity. J Investig Allergol Clin Immunol 2023; 33:281-288. [PMID: 35503227 DOI: 10.18176/jiaci.0816] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/28/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Comorbidities can influence asthma control and promote asthma exacerbations (AEs). However, the impact of multimorbidity in AEs, assessed based on long-term follow-up of patients with asthma of different degrees of severity, has received little attention in real-life conditions. To describe the epidemiological and clinical characteristics and predictors of AEs in patients who had presented at least 1 AE in the previous year in the MEchanism of Genesis and Evolution of Asthma (MEGA) cohort. METHODS The work-up included a detailed clinical examination, pulmonary function testing, fractional exhaled nitric oxide (FeNO), blood counts, induced sputum, skin prick-tests, asthma questionnaires, and assessment of multimorbidity. The number of moderate-severe AEs in the preceding year was registered for each patient. RESULTS The study population comprised 486 patients with asthma (23.7% mild, 35% moderate, 41.3% severe). Disease remained uncontrolled in 41.9%, and 47.3% presented ≥1 moderate-severe AE, with a mean (SD) annual exacerbation rate of 0.47 (0.91) vs 2.11 (2.82) in mild and severe asthma, respectively. Comorbidity was detected in 56.4% (66.6% among those with severe asthma). Bronchiectasis, chronic rhinosinusitis with nasal polyps, atopy, psychiatric illnesses, hyperlipidemia, and hypertension were significantly associated with AEs. No associations were found for FeNO, blood eosinophils, or total serum IgE. Sputum eosinophilia and a high-T2 inflammatory pattern were significantly associated with AEs. Multivariable regression analysis showed a significant association with asthma severity, uncontrolled disease, and low prebronchodilator FEV1/FVC. CONCLUSION Our study revealed a high frequency of AE in the MEGA cohort. This was strongly associated with multimorbidity, asthma severity, poor asthma control, airflow obstruction, higher sputum eosinophils, and a very high-T2 inflammatory pattern.
Collapse
Affiliation(s)
- J Domínguez-Ortega
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - J A Luna-Porta
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - J M Olaguibel
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Severe Asthma Unit, Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - P Barranco
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - B Barroso
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - D Betancor
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - I Bobolea
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - M L Caballero
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Immunology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain
- Pneumology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - E Curto
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Barcelona, Spain
- Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
| | - F J González-Barcala
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Pneumology Department, Complejo Hospitalario Universitario de Santiago, La Coruña, Spain
- Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), La Coruña, Spain
- Universidad de Santiago de Compostela, La Coruña, Spain
| | - I Losantos-García
- Institute for Health Research IdiPAZ, Madrid, Spain
- Biostatistics Department, La Paz University Hospital, Madrid, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
- Pneumology Department, Hospital Germans Trias i Pujol, Barcelona, Spain
- Institut d'Investigacio Germans Trias I Pujol (IGTP), Badalona, Barcelona, Spain
| | - P Mendez-Brea
- Department of Allergy, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain
| | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Pneumology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - C Picado
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Plaza
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Barcelona, Spain
- Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Immunology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - J Sastre
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - L Soto
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Barcelona, Spain
- Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - M Valverde-Monge
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - S Quirce
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
6
|
Loli-Ausejo D, Perdomo G, Mascaró B, Martínez-Olondris P, Sánchez-Fernández MC, Mullol J, Valero A, Arismendi E, Bobolea I. Mepolizumab treatment for severe eosinophilic asthma: a 5-years real-life experience. J Investig Allergol Clin Immunol 2023:0. [PMID: 36820628 DOI: 10.18176/jiaci.0898] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023] Open
Affiliation(s)
- D Loli-Ausejo
- Department of Allergy, Hospital Clínic Barcelona, Barcelona, Spain.,Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain
| | - G Perdomo
- Department of Allergy, Hospital Santa Creu i Sant Pau, Barcelona, Spain
| | - B Mascaró
- Department of Allergy, Hospital Clínic Barcelona, Barcelona, Spain.,Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain
| | - P Martínez-Olondris
- Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain.,Department of Pneumology, Hospital Clínic Barcelona, Barcelona, Spain
| | | | - J Mullol
- Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain.,Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic Barcelona, Universitat de Barcelona, Barcelona, Spain.,CIBER of Respiratory Diseases (CIBERES), Health Institute Carlos III
| | - A Valero
- Department of Allergy, Hospital Clínic Barcelona, Barcelona, Spain.,Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain.,CIBER of Respiratory Diseases (CIBERES), Health Institute Carlos III
| | - E Arismendi
- Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain.,Department of Pneumology, Hospital Clínic Barcelona, Barcelona, Spain.,CIBER of Respiratory Diseases (CIBERES), Health Institute Carlos III
| | - I Bobolea
- Department of Allergy, Hospital Clínic Barcelona, Barcelona, Spain.,Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain.,CIBER of Respiratory Diseases (CIBERES), Health Institute Carlos III
| |
Collapse
|
7
|
Barroso B, Valverde-Monge M, Alobid I, Olaguibel JM, Rial MJ, Quirce S, Arismendi E, Barranco P, Betancor D, Bobolea I, Cárdaba B, Cruz Carmona MJ, Curto E, Domínguez-Ortega J, González-Barcala FJ, Martínez-Rivera C, Mahíllo-Fernández I, Muñoz X, Picado C, Plaza V, Rodrigo Muñoz JM, Soto-Retes L, Valero A, Del Pozo V, Mullol J, Sastre J. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study. J Investig Allergol Clin Immunol 2023; 33:37-44. [PMID: 35416154 DOI: 10.18176/jiaci.0812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Chronic rhinosinusitis with nasal polyps (CRSwNP), which is characterized by partial loss of smell (hyposmia) or total loss of smell (anosmia), is commonly associated with asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). CRSwNP worsens disease severity and quality of life. The objective of this real-world study was to determine whether biological treatments prescribed for severe asthma can improve olfaction in patients with CRSwNP. A further objective was to compare the improvement in in olfaction in N-ERD and non-N-ERD subgroups. METHODS We performed a multicenter, noninterventional, retrospective, observational study of 206 patients with severe asthma and CRSwNP undergoing biological treatment (omalizumab, mepolizumab, benralizumab, or reslizumab). RESULTS Olfaction improved after treatment with all 4 monoclonal antibodies (omalizumab [35.8%], mepolizumab [35.4%], reslizumab [35.7%], and benralizumab [39.1%]), with no differences between the groups. Olfaction was more likely to improve in patients with atopy, more frequent use of short-course systemic corticosteroids, and larger polyp size. The proportion of patients whose olfaction improved was similar between the N-ERD (37%) and non-N-ERD (35.7%) groups. CONCLUSIONS This is the first real-world study to compare improvement in olfaction among patients undergoing long-term treatment with omalizumab, mepolizumab, reslizumab, or benralizumab for severe asthma and associated CRSwNP. Approximately 4 out of 10 patients reported a subjective improvement in olfaction (with nonsignificant differences between biologic drugs). No differences were found for improved olfaction between the N-ERD and non-N-ERD groups.
Collapse
Affiliation(s)
- B Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - M Valverde-Monge
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Alobid
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain
| | - J M Olaguibel
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Allergy Department, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Allergy Department, Hospital Juan Canalejo, A Coruña, Spain
| | - S Quirce
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Department of Allergy, La Paz University Hospital, Madrid, Spain.,Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.,Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - P Barranco
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Department of Allergy, La Paz University Hospital, Madrid, Spain.,Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - D Betancor
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Bobolea
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.,Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz Carmona
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology Department, Hospital Universitari Vall d´Hebron, Barcelona, Spain
| | - E Curto
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J Domínguez-Ortega
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Department of Allergy, La Paz University Hospital, Madrid, Spain.,Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - F J González-Barcala
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology Department, Hospital Germans Trias i Pujol, Badalona, Spain
| | | | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology Department, Hospital Universitari Vall d´Hebron, Barcelona, Spain.,Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - C Picado
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.,Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Plaza
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J M Rodrigo Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - L Soto-Retes
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.,Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain
| | - J Sastre
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
8
|
González O, Picado C, Arismendi E, Alobid I, Ramirez J, Valero A, Bobolea I. Eosinophilic sialodochitis: a rare comorbidity of severe asthma. J Investig Allergol Clin Immunol 2022; 33:139-140. [PMID: 35503510 DOI: 10.18176/jiaci.0817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- O González
- Allergy Department, General University Hospital of Ciudad Real, Ciudad Real, Spain
| | - C Picado
- Allergy Section, Pulmonology and Respiratory Allergy Department, Hospital Clínic, Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - E Arismendi
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Pulmonology Department, Hospital Clínic, Barcelona, Spain
| | - I Alobid
- Otorhinolaryngology Department, Hospital Clínic, University of Barcelona, Spain
| | - J Ramirez
- Histopathology Department, Hospital Clínic, Barcelona, Spain
| | - A Valero
- Allergy Section, Pulmonology and Respiratory Allergy Department, Hospital Clínic, Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - I Bobolea
- Allergy Section, Pulmonology and Respiratory Allergy Department, Hospital Clínic, Barcelona, Spain
- Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
9
|
Bobolea I, Bañas D, Melero C, de Andrés AI, Joksaite S, Sánchez-Herrero G. Exacerbation Rate Reduction with Mepolizumab, Stratified by Maintenance OCS Use and Eosinophil Levels. A Post-Hoc Analysis of DREAM and MENSA Studies. J Investig Allergol Clin Immunol 2021; 32:148-150. [PMID: 34085935 DOI: 10.18176/jiaci.0714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- I Bobolea
- Allergy Section, Severe Asthma Unit. Department of Pulmonology and Allergy, Hospital Clinic Barcelona- Institute for Health Research (IdiBAPS)
| | | | - C Melero
- Hospital 12 de Octubre Institute for Health Research (i+12), Madrid, Spain
| | | | | | | |
Collapse
|
10
|
Díaz-Campos RM, Bobolea I, Girón-Matute W, Guillén-Vera D, De Las Cuevas-Moreno N, Melero-Moreno C. Autoimmune Diseases and Asthma. J Investig Allergol Clin Immunol 2020; 29:246-248. [PMID: 31219041 DOI: 10.18176/jiaci.0371] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R M Díaz-Campos
- Pneumology Service, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - I Bobolea
- Allergology Service, Hospital Universitario Clinic de Barcelona, Barcelona, Spain
| | - W Girón-Matute
- Pneumology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - D Guillén-Vera
- Institute for Health Research (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain
| | - N De Las Cuevas-Moreno
- Institute for Health Research (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain
| | - C Melero-Moreno
- Institute for Health Research (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
11
|
Izquierdo-Domínguez A, Bobolea I, Doña I, Campo P, Segura C, Ortega N, González R, Delgado J, Torres MJ, Dordal MT. Statement of the Spanish Society of Allergology and Clinical Immunology on Provocation Tests With Aspirin/Nonsteroidal Anti-inflammatory Drugs. J Investig Allergol Clin Immunol 2019; 30:1-13. [PMID: 31530511 DOI: 10.18176/jiaci.0449] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used throughout the world. They are frequently involved in hypersensitivity reactions, which range from local or mild reactions to systemic and severe reactions. Consequently, it is necessary to perform an exhaustive study of patients in order to make an accurate diagnosis, search for safe procedures in the case of severe reactions, and identify alternative treatment options. Various guidelines and protocols address the management of hypersensitivity to NSAIDs, although these vary widely from country to country. The Committees of Asthma, Rhinoconjunctivitis, and Drug Allergy of the Spanish Society of Allergy and Clinical Immunology (SEAIC) propose the present position statement on available options for provocation testing with aspirin/NSAIDs. This document is the fruit of an exhaustive review of current evidence and is based on recent publications addressing the diagnosis of patients with hypersensitivity to NSAIDs and on a consensus-oriented discussion among a group of experts from the SEAIC. The main objective was to draft an easy-toread, practical guideline for health care professionals in specialist areas who assess and manage patients with suspected hypersensitivity to NSAIDs. Furthermore, indications, contraindications, and procedures for oral, bronchial, and nasal provocation tests with aspirin/NSAIDs have been updated.
Collapse
Affiliation(s)
- A Izquierdo-Domínguez
- Allergy Service, Consorci Sanitari de Terrassa, Barcelona, Spain.,Allergy Unit, Clínica Diagonal, Barcelona, Spain
| | - I Bobolea
- Allergy Section, Servei de Pneumologia i Al.lèrgia Respiratòria, Hospital Clínic, Barcelona, Spain
| | - I Doña
- Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.,Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain
| | - P Campo
- Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.,Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain
| | - C Segura
- UGC Alergología, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - N Ortega
- Allergy Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
| | - R González
- Allergy Service, Hospital Universitario de Canarias, Tenerife, Spain
| | - J Delgado
- UGC Alergología, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - M J Torres
- Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.,Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain
| | - M T Dordal
- Allergy Unit, Servei de Medicina Interna, Hospital Universitari de Bellvitge, Barcelona, Spain
| | | |
Collapse
|
12
|
Bobolea I, Arismendi E, Valero A, Agustí A. Early Life Origins of Asthma: A Review of Potential Effectors. J Investig Allergol Clin Immunol 2018; 29:168-179. [PMID: 30561365 DOI: 10.18176/jiaci.0361] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
There is growing evidence that events occurring early in life, both before and after birth, are significantly associated with the risk of asthma, chronic obstructive pulmonary disease, and diminished lung function later in life. In fact, from conception to death, a series of continuous, dynamic gene-environment interactions determine 2 fundamental biological processes, namely, lung development and lung aging. Over 130 birth cohorts have been initiated in the last 30 years. Data from these cohorts have improved our understanding of the inception, progression, and persistency of asthma. In this review, we summarize the main data for the early life events proven to determine later development and persistence of asthma, such as maternal atopy and smoking, preterm birth/bronchopulmonary dysplasia, infections, nutrition, obesity, smoking, and other environmental exposures in childhood and adolescence. While some of these factors are obviously impossible to prevent or eliminate, others have been proven to have a protective role, and current research is aimed optimizing them. Available prophylactic measures are also reviewed. In the case of environmental pollution, large scale political interventions successfully managed to decrease contamination levels, leading to improved lung function and lower asthma prevalence in the respective geographical areas. Future research should focus on better understanding these complex interactions in order to develop and enhance effective preventive therapeutic measures.
Collapse
Affiliation(s)
- I Bobolea
- Respiratory Institute, Hospital Clínic, Barcelona, Spain.,University of Barcelona, Barcelona, Spain.,Institut d'Investigacio Biomedica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Spain
| | - E Arismendi
- Institut d'Investigacio Biomedica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Spain
| | - A Valero
- Respiratory Institute, Hospital Clínic, Barcelona, Spain.,University of Barcelona, Barcelona, Spain.,Institut d'Investigacio Biomedica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Spain
| | - A Agustí
- Respiratory Institute, Hospital Clínic, Barcelona, Spain.,University of Barcelona, Barcelona, Spain.,Institut d'Investigacio Biomedica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Spain
| |
Collapse
|
13
|
Sastre J, Crespo A, Fernandez-Sanchez A, Rial M, Plaza V, González FC, López JJ, Riaza MM, Orenes MM, Montaño PP, Toro MT, Balaguer CA, Girones MA, Martinez CB, Martín IF, Delgado PG, Calahorro MM, Carrasco GM, Pacheco RR, Tomás VV, Godoy MM, Yébenes JZ, Balza De Vallejo OV, Fernandez JA, Gonzalez TB, De Las Pozas GC, Donado CD, Angulo SD, Ortiz GG, Mañana BR, Gonzalez RB, Nieves EG, Torrado JM, Culla MD, Pla JJ, Bellfill RL, Velasco JM, Nogues EP, Ortun MR, Aguñin PR, Farre NS, Combas JV, Zubeldia IA, Hortigüela GB, Ayuso JC, Álvarez GG, Peña MH, Castro AL, Llorente PL, Martinez PM, Malanda NM, Gonzalez FG, Miguel TP, Hernandez M, Timon SJ, Carreño SP, Olbah MA, Muñoz AA, Mohedad JC, Fernandez DG, Camacho AL, Lopez CM, Gonzalez MM, Bernal SN, Pellon LF, Miguel EM, Portal FO, Rodríguez AS, Alapont MM, Raducan I, Segarra MS, Bonilla PG, Calderon PM, Rodriguez MM, Martinez RL, Pérez MM, Villarejo MM, Aparicio MB, Muíño Joga MD, Garcia-Boente LF, Paz VG, Barcala FG, Orjales RN, Castedo CR, Diaz MR, Fernandez AM, Español SA, San Francisco AR, Navarrete BA, Gomez De Cadiz LC, Rodriguez ME, Lopez JF, Jiménez ML, Caballero JL, Ceres MM, Costoya RM, García CM, Vilchez MR, Ortiz AR, Mazuecos JB, Castro AV, Arenaza BL, Mendizabal SL, Sampedro IP, Vazquez LV, De Sus JC, Villa JC, Pargada DF, Jarque JH, Patiño MC, Gomila AF, Pastrie FN, Lopez JA, Martinez PB, Ruiz De Lobera AV, Gonzalez FC, Carral CP, Racamonde AV, Del Pino MC, Sacanell JR, García IA, Mejias YA, Bausela BA, Cozar MA, Sanz PB, Bobolea I, Fernandez AB, De Santiago Delgado E, Campos RD, Uña JD, Vila AF, Cano MG, De Pedro JG, Galicia MG, De Olano DG, Barbudo BH, Viña AL, Peña AL, Martin GM, De Francisco AM, Borque RM, Moro M, Prieto MR, Frutos MR, Jimenez BR, Rodríguez M, Ribate DR, Perez FR, Hornillos JR, López PS, Martinez FS, Garrido-Lestache JS, Gambasica ZV, Albelda CV, Ramirez JA, De Luiz Martínez G, Núñez IG, De Luna FL, Sáenz De Tejada EO, Galo AP, Martinez RR, Esojo MS, Espinosa RA, Inglés MA, Mora RB, Campos MF, Arellano MP, Puebla MA, Figueroa BG, Fernández SG, Rivera JO, Purroy AT, Garazo BP, Losada SV, Villamuza YG, Bonny JC, Sintes RA, Landin JC, Paz AC, Abelaira MC, Rio FI, Sanmartín AP, Picans I, Moreira AR, Romera RT, Aznar JI, Bellido FM, Hernandez MR, Perez RG, Flores HI, Gutierrez FA, Cimbollek S, De Luque Piñana V, Gallardo JM, Garcia VM, Cuevas JO, Crespo YP, Enriquez JQ, Dominguez PS, Elias ÒS, Pamplona MM, Lara MJ, De Gregorio AM, Martin MA, Canelles MB, Baixauli EB, Serra PC, Gregori MC, Rodriguez PC, De Las Marinas Alvarez M, Palacios MD, El-Qutob López D, Giner JG, Lara SH, Martínez GJ, Santafé JL, Bayo AL, Moragon EM, Sancho IM, Lacomba JM, Sendra EN, Seisdedos LN, Bertol BO, Iniesta AR, Cubillan JR, Sánchez-Toril López F, Vinuesa AS, Gomez AA, De Frutos Arribas J, Fernandez EM, Alonso AS, Sanz CC, Fuentes MD, Sotillos MG, Arazuri NS. Anxiety, Depression, and Asthma Control: Changes After Standardized Treatment. The Journal of Allergy and Clinical Immunology: In Practice 2018; 6:1953-1959. [DOI: 10.1016/j.jaip.2018.02.002] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Revised: 01/28/2018] [Accepted: 02/01/2018] [Indexed: 11/28/2022]
|
14
|
Blanco D, Ruiz Sancho V, Barranco R, Fernández C, Bobolea I. [Hypersensitivity to non-steroidal anti-inflammatory drugs, food allergy and mast cell activation syndrome: Relevance of the full allergy testing panel and a brief review of the subject, including two clinical case reports]. Semergen 2018; 44:506-508. [PMID: 30206037 DOI: 10.1016/j.semerg.2018.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 04/30/2018] [Indexed: 10/28/2022]
Affiliation(s)
- D Blanco
- Servicio de Alergología, Hospital Universitario 12 de Octubre, i+12, Madrid, España.
| | - V Ruiz Sancho
- Servicio de Alergología, Hospital Universitario 12 de Octubre, i+12, Madrid, España
| | - R Barranco
- Servicio de Alergología, Hospital Universitario 12 de Octubre, i+12, Madrid, España
| | - C Fernández
- Servicio de Alergología, Hospital Universitario 12 de Octubre, i+12, Madrid, España
| | - I Bobolea
- Servicio de Neumología y Alergia respiratoria, ICR, Hospital Clínic, Barcelona, España
| |
Collapse
|
15
|
Belver M, Michavila A, Bobolea I, Feito M, Bellón T, Quirce S. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS). Allergol Immunopathol (Madr) 2016; 44:83-95. [PMID: 26089185 DOI: 10.1016/j.aller.2015.02.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2014] [Revised: 01/31/2015] [Accepted: 02/13/2015] [Indexed: 12/17/2022]
Abstract
Severe delayed drug-induced skin reactions in children are not common but potentially serious. This article describes aspects concerning the etiology, pathogenesis and clinical manifestations of these processes; it presents three paediatric cases, namely STS (Steven Johnson Syndrome), TEN (toxic epidermal necrolysis), probably related to amoxicillin/clavulanate and ibuprofen and DRESS (a drug reaction with eosinophilia and systemic symptoms) secondary to phenytoin; and in relation to them, the diagnosis and the treatment of these processes are discussed and reviewed. The AGEP (acute generalised exanthematous pustulosis) is also reviewed. The aetiological diagnosis of severe non-immediate reactions is difficult, and the value of current allergological testing is not well defined in these cases. Diagnosis is based on clinical history, the empirical risk of drugs to trigger SJS/TEN or DRESS, and the in vivo and in vitro testing of the suspect drug. Skin biopsy confirms that the clinical diagnosis and delayed hypersensitivity tests, especially the patch test and the lymphoblastic transformation test (LTT), may be important to confirm the aetiological diagnosis, in our cases emphasising the latter. These diseases can be life threatening (especially DRESS and TEN) and/or have a high rate of major complications or sequelae (SJS/TEN). The three cases described progressed well without sequelae. All were treated with corticosteroids, which is the most currently accepted treatment although the effect has not been clearly demonstrated.
Collapse
|
16
|
Kimura H, Suzuki M, Konno S, Nishimura M, Bobolea I, Barranco P, del Pozo V, Romero D, Sanz V, López-Carrasco V, Canabal J, Villasante C, Quirce S. Sputum periostin in patients with different severe asthma phenotypes. Allergy 2015; 70:884-5. [PMID: 26081263 DOI: 10.1111/all.12639] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- H. Kimura
- First Department of Medicine; Hokkaido University School of Medicine; Sapporo Japan
| | - M. Suzuki
- First Department of Medicine; Hokkaido University School of Medicine; Sapporo Japan
| | - S. Konno
- First Department of Medicine; Hokkaido University School of Medicine; Sapporo Japan
| | - M. Nishimura
- First Department of Medicine; Hokkaido University Hospital; Sapporo Japan
| | - I. Bobolea
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - P. Barranco
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
- Spanish Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES); Madrid Spain
| | - V. del Pozo
- Spanish Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES); Madrid Spain
- Department of Immunology; IIS-Fundación Jiménez Díaz; Madrid Spain
| | - D. Romero
- Department of Pneumology; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - V. Sanz
- Spanish Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES); Madrid Spain
- Department of Immunology; IIS-Fundación Jiménez Díaz; Madrid Spain
| | - V. López-Carrasco
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - J. Canabal
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - C. Villasante
- Department of Pneumology; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - S. Quirce
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
- Spanish Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES); Madrid Spain
| |
Collapse
|
17
|
Bobolea I, Barranco P, Del Pozo V, Romero D, Sanz V, López-Carrasco V, Canabal J, Villasante C, Quirce S. Sputum periostin in patients with different severe asthma phenotypes. Allergy 2015; 70:540-6. [PMID: 25631525 DOI: 10.1111/all.12580] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/23/2015] [Indexed: 02/03/2023]
Abstract
BACKGROUND Identifying inflammatory phenotypes is relevant in severe uncontrolled asthma. The aim of this study was to identify the different clinical, inflammatory, functional, and molecular phenotypes in patients with severe asthma and to investigate the potential role of sputum periostin as a biomarker of severe asthma phenotypes. PATIENTS AND METHODS Sputum induction was performed in 62 patients diagnosed with severe asthma. Skin prick testing, lung function tests, exhaled nitric oxide, hematimetry, and total serum IgE were performed. Periostin was measured in sputum supernatants. RESULTS Patients with asthma were phenotyped and 80% had late-onset asthma, 50% had fixed airflow obstruction, and 66% showed a Th2-high phenotype. With respect to inflammatory phenotypes, 71% were eosinophilic and 25% mixed granulocytic. Periostin levels were higher in patients with fixed as compared to variable airflow limitation (69.76 vs 43.84 pg/ml, P < 0.05) and in patients with eosinophilic as compared to mixed granulocytic phenotype (61.58 vs 37.31 pg/ml, P < 0.05). There was an inverse correlation between postbronchodilator FEV1 /FVC and periostin levels (-0.276, P < 0.05). CONCLUSION This study demonstrates the utility of periostin in phenotyping severe asthma. Periostin levels in sputum are associated with persistent airflow limitation in asthma patients with airway eosinophilia despite treatment with high-dose inhaled corticosteroids.
Collapse
Affiliation(s)
- I. Bobolea
- Department of Allergy; Hospital 12 de Octubre Institute for Health Research (i+12); Madrid Spain
| | - P. Barranco
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
- Spanish Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES); Madrid Spain
| | - V. Del Pozo
- Spanish Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES); Madrid Spain
- Department of Immunology; IIS-Fundación Jiménez Díaz; Madrid Spain
| | - D. Romero
- Department of Pneumology; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - V. Sanz
- Spanish Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES); Madrid Spain
- Department of Immunology; IIS-Fundación Jiménez Díaz; Madrid Spain
| | - V. López-Carrasco
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - J. Canabal
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - C. Villasante
- Department of Pneumology; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - S. Quirce
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
- Spanish Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES); Madrid Spain
| |
Collapse
|
18
|
Rijo Y, Canabal J, Fiandor A, Bobolea I, Quirce S, Cabañas R. Aspirin desensitization in a patient with NSAID-induced delayed angioedema. J Investig Allergol Clin Immunol 2015; 25:156-158. [PMID: 25997319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023] Open
|
19
|
Guillén D, Bobolea I, Calderon O, Fiandor A, Heredia R, Quirce S. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease. J Investig Allergol Clin Immunol 2015; 25:133-135. [PMID: 25997307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023] Open
|
20
|
Cabañas R, Calderon O, Ramirez E, Fiandor A, Prior N, Caballero T, Herránz P, Bobolea I, López-Serrano MC, Quirce S, Bellón T. Piperacillin-induced DRESS: distinguishing features observed in a clinical and allergy study of 8 patients. J Investig Allergol Clin Immunol 2014; 24:425-430. [PMID: 25668894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023] Open
Abstract
BACKGROUND DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome is characterized by fever, rash, eosinophilia, and multiorgan failure. Previous reports have described differences in clinical and laboratory findings of DRESS syndrome depending on the inducing drug. Piperacillin has been reported as the drug responsible for this syndrome in 3 patients. OBJECTIVE To analyze and describe the clinical, laboratory, and allergy study findings of piperacillin-induced DRESS. PATIENTS AND METHODS Retrospective case series of patients diagnosed with DRESS associated with piperacillin-tazobactam (Pip/Taz) according to the Kardaun diagnostic score criteria. Assessment of causality was established using the Spanish Pharmacovigilance System and the lymphocyte transformation test (LTT). The allergy study included skin and epicutaneous tests. RESULTS Eight patients were diagnosed with DRESS due to Pip/Taz (3 probable and 5 definite cases). Skin rash was observed in all cases and facial edema in 50%; the mean latency period was 18 days. Fever was present in 7 patients. Liver and kidney injuries were detected in 6 and 3 patients, respectively. All patients had eosinophilia and a full recovery. The LTT to Pip/Taz was strongly positive in all patients, with a stimulation index of over 6. Three of 3 patients had a positive intradermal test to Pip/Taz, and 1 of 4 had a positive patch test. All patients had a negative LTT to carbapenems. CONCLUSIONS We have reported on the first case series of piperacillin-induced DRESS. A latency period of 18 days, skin rash, eosinophilia, fever, liver injury, and good prognosis were the most common features. The allergy study, and the LTT in particular, was highly useful for identifying Pip/Taz as the culprit drug and piperacillin as the responsible active ingredient.
Collapse
|
21
|
Ramírez E, Cabañas R, Laserna LS, Fiandor A, Tong H, Prior N, Calderón O, Medrano N, Bobolea I, Frías J, Quirce S. Proton pump inhibitors are associated with hypersensitivity reactions to drugs in hospitalized patients: a nested case-control in a retrospective cohort study. Clin Exp Allergy 2013; 43:344-52. [PMID: 23414543 DOI: 10.1111/cea.12034] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Revised: 08/27/2012] [Accepted: 08/29/2012] [Indexed: 11/30/2022]
Abstract
BACKGROUND Previous research has shown that gastric acid suppression by antacid drugs can promote allergic reactions to acid-labile food proteins. No data are available about whether antacid drugs can promote drug hypersensitivity reactions. The most potent and longer lasting inhibition of gastric secretion is provided by proton pump inhibitors (PPIs). We hypothesized that gastric acid suppression by proton pump inhibitors could be causative of drug hypersensitivity reactions during hospitalization. OBJECTIVE To estimate the risk of developing drug hypersensitivity reactions during the hospitalization of patients treated with proton pump inhibitors, and other associated factors. METHODS A nested case-control in a retrospective cohort study of hospitalized patients from September 2008 to December 2010 (70 771 admissions) was conducted using the registry of cases of interconsultations to the Allergy Department (161 confirmed cases of drug hypersensitivity reactions). A total of 318 controls were matched by first drug suspected in the hypersensitivity reaction, time of admission, age, gender and hospitalization wards. RESULTS The relative risk of drug hypersensitivity reaction occurrence during hospitalization of patients treated with PPIs compared with those not treated in the period of study was significant (RR: 3.97; 95% CI: 1.97-8.29). After controlling for confounders in the nested case-control cohort, the use of PPIs persists as a predisposing factor (OR: 4.35; 95% CI: 2-9.45). Personal history of drug allergy and a long hospitalization time were other predisposing factors of drug hypersensitivity reactions (DHRs). The hazard that a DHR has occurred during PPI treatment was 3.7% per day. The hazard for immediate or accelerated reactions was 1.706 (P = 0.003) times that of delayed reactions. CONCLUSION AND CLINICAL RELEVANCE In hospitalized patients, the use of proton pump inhibitors was associated with a significant increase risk of drug hypersensitivity reactions along with a personal history of drug allergies and long hospitalization time.
Collapse
Affiliation(s)
- E Ramírez
- Department of Clinical Pharmacology, Hospital La Paz Health Research Institute (IdiPAZ), School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Cancelliere N, Bobolea I, López-Carrasco V, Barranco P, López-Serrano C, Quirce S. Comparative study of bronchial hyperresponsiveness to methacholine and mannitol in the initial diagnosis of asthma. J Investig Allergol Clin Immunol 2013; 23:361-362. [PMID: 24260983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023] Open
Affiliation(s)
- N Cancelliere
- Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
23
|
Barranco P, Delgado J, Gallego LT, Bobolea I, Pedrosa M, García de Lorenzo A, Quirce S. [Asthma, obesity and diet]. NUTR HOSP 2012; 27:138-45. [PMID: 22566313 DOI: 10.1590/s0212-16112012000100016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2011] [Accepted: 09/20/2011] [Indexed: 11/22/2022] Open
Abstract
Asthma and obesity have a considerable impact on public health and their prevalence has increased in recent years. Numerous studies have linked both disorders. Most prospective studies show that obesity is a risk factor for asthma and have found a positive correlation between baseline body mass index (BMI) and the subsequent development of asthma, although these results are not conclusive when studying the association between airway hyperresponsiveness with BMI. Furthermore, several studies suggest that whereas weight gain increases the risk of asthma, weight loss improves the course of the illness. Different factors could explain this association. Obesity is capable of reducing pulmonary compliance, lung volumes and the diameter of peripheral respiratory airways as well as affecting the volume of blood in the lungs and the ventilation-perfusion relationship. Furthermore, the increase in the normal functioning of adipose tissue in obese subjects leads to a systemic proinflammatory state, which produces a rise in the serum concentrations of several cytokines, the soluble fractions of their receptors and chemokines. Many of these mediators are synthesized and secreted by cells from adipose tissue and receive the generic name of adipokines, including IL-6, IL-10, eotaxin, TNF-α, TGF- 1, PCR, leptin y adiponectin. Finally, specific regions of the human genome which are related to both asthma and obesity have been identified. Most studies point out that obesity is capable of increasing the prevalence and incidence of asthma, although this effect appears to be modest. The treatment of obese asthmatics must include a weight control program.
Collapse
Affiliation(s)
- P Barranco
- Servicio Alergología, Hospital La Paz, IdiPAZ, Madrid, España.
| | | | | | | | | | | | | |
Collapse
|
24
|
Barranco P, Olalde S, Caminoa M, Bobolea I, Caballero T, del Pozo V, Quirce S. Occupational asthma due to western red cedar in a guitar maker. J Investig Allergol Clin Immunol 2012; 22:293-294. [PMID: 22812202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
Affiliation(s)
- P Barranco
- Departament of Allergy, Hospital La Paz Health Research Institute (IdiPAZ), Madrid, Spain.
| | | | | | | | | | | | | |
Collapse
|
25
|
García-Ara MC, Bobolea I, Caballero T, Quirce S, Boyano-Martínez MT. Specific immunoglobulin E to Echinococcus granulosus in children allergic to cow's milk proteins. J Investig Allergol Clin Immunol 2012; 22:374-375. [PMID: 23101315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
Affiliation(s)
- M C García-Ara
- Department of Allergy, Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain
| | | | | | | | | |
Collapse
|
26
|
Martín-Muñoz MF, Bartolome B, Caminoa M, Bobolea I, Ara MCG, Quirce S. Bee pollen: a dangerous food for allergic children. Identification of responsible allergens. Allergol Immunopathol (Madr) 2010; 38:263-5. [PMID: 20447747 DOI: 10.1016/j.aller.2009.12.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2009] [Accepted: 12/03/2009] [Indexed: 11/17/2022]
Abstract
BACKGROUND Bee pollen has been proposed as a food supplement, but it can be a dangerous food for people with allergy. We study an allergic reaction after ingestion of bee pollen in a 4-year-old boy who had developed rhinitis in the last spring and autumn. METHODS We performed a prick-by-prick test with bee pollen and skin prick tests with the most important local pollens, house dust mites, common fungi, and animal danders. The levels of serum tryptase, serum total IgE and specific IgE against bee venom and local pollen extracts were determined. The composition of the bee pollen was analysed and SDS-PAGE immunoblotting and blotting-inhibition were carried out. RESULTS Prick tests were positive to bee pollen and all local pollens extracts and negative to any other allergen sources. The bee pollen sample contained pollens from Quercus genus, and Asteraceae (Compositae) and Rosaceae families. Total IgE was 435 kU/l. Serum specific IgE to bee pollen was 6 kU/l and greater than 0.35 kU/L against pollens from Artemisia vulgaris, Taraxacum officinalis, Cupressus arizonica, Olea europaea, Platanus acerifolia and Lolium perenne as well as to n Art v 1 and other pollen marker allergens. Tryptase level was 3.5 mcg/mL. SDS-PAGE immunoblotting-inhibition points to Asteraceae pollen as the possible cause of the allergic reaction. CONCLUSION Foods derived from bees can be dangerous to people with allergy to pollen.
Collapse
|
27
|
Caminoa M, Martín-Muñoz M, de la Losa FP, García GGP, Bobolea I, Larco J, Diaz-Pena J, Quirce S. Hidden Allergens in Breast Milk. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.864] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Bobolea I, Barranco P, Fiandor A, Cabañas R, Quirce S. Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 2010; 20:448-449. [PMID: 20945617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
MESH Headings
- Adolescent
- Antibodies, Anti-Idiotypic
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal, Humanized
- Antigens, Plant/immunology
- Asthma, Aspirin-Induced/diagnosis
- Asthma, Aspirin-Induced/etiology
- Asthma, Aspirin-Induced/physiopathology
- Asthma, Aspirin-Induced/prevention & control
- Bronchial Spasm
- Common Cold/complications
- Common Cold/diagnosis
- Common Cold/drug therapy
- Common Cold/physiopathology
- Female
- Humans
- Ibuprofen/administration & dosage
- Ibuprofen/adverse effects
- Nasal Obstruction
- Omalizumab
- Poaceae
- Pollen
- Quality of Life
- Respiratory Function Tests
- Rhinitis, Allergic, Seasonal/complications
- Rhinitis, Allergic, Seasonal/diagnosis
- Rhinitis, Allergic, Seasonal/drug therapy
- Rhinitis, Allergic, Seasonal/physiopathology
Collapse
Affiliation(s)
- I Bobolea
- Allergy Department, Hospital Universitario La Paz, Madrid, Spain.
| | | | | | | | | |
Collapse
|
29
|
Bobolea I, Barranco P, Jurado-Palomo J, Pedrosa M, Quirce S. Allergy to dry fermented sausage. J Investig Allergol Clin Immunol 2009; 19:324-325. [PMID: 19639733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
MESH Headings
- Allergens/immunology
- Angioedema
- Antigens, Fungal/immunology
- Asthma/etiology
- Conjunctivitis/etiology
- Food Contamination
- Food Hypersensitivity/blood
- Food Hypersensitivity/complications
- Food Hypersensitivity/diagnosis
- Food Hypersensitivity/immunology
- Food Hypersensitivity/physiopathology
- Humans
- Immunoglobulin E/blood
- Male
- Meat Products
- Penicillium/immunology
- Pollen/immunology
- Rhinitis, Allergic, Seasonal/blood
- Rhinitis, Allergic, Seasonal/complications
- Rhinitis, Allergic, Seasonal/diagnosis
- Rhinitis, Allergic, Seasonal/immunology
- Rhinitis, Allergic, Seasonal/physiopathology
- Young Adult
Collapse
Affiliation(s)
- I Bobolea
- Department of Allergology, Hospital Universitario La Paz, Madrid, Spain
| | | | | | | | | |
Collapse
|
30
|
Barranco P, Bobolea I, Larco JI, Prior N, López-Serrano MC, Quirce S. Diagnosis of aspirin-induced asthma combining the bronchial and the oral challenge tests: a pilot study. J Investig Allergol Clin Immunol 2009; 19:446-452. [PMID: 20128418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Abstract
BACKGROUND We investigated the usefulness of the bronchial challenge (BC) with lysine-acetylsalicylate (L-ASA) in the diagnosis of aspirin-exacerbated respiratory disease (AERD) using a protocol that combined both the oral challenge (OC) and the BC tests. METHODS Adult asthmatic patients with suspected AERD who underwent BC with L-ASA were included in the study. If the BC result with L-ASA was negative, an OC was carried out to establish the diagnosis. AERD was ruled out if both the BC and the OC results were negative (nonresponders). Both responders and nonresponders were compared for age, gender, a personal or family history of atopy, underlying disease, current asthma treatment, and presence of nasal polyps. Six patients with asthma but no suggestive history of AERD were included as controls. RESULTS Twenty-two patients completed the study. Ten patients tested positive to the BC and/or OC (responders), whereas 12 did not (nonresponders). Seven out of the 10 responders had a positive BC result and 3 a positive OC result. After BC, 4 patients had an early asthmatic response, 1 had a dual response, and 2 had isolated late responses. No significant differences were observed in the aforementioned variables between responders and nonresponders. The results of both challenges were negative in the 6 controls. CONCLUSIONS The BC had a high positive predictive value, was safe, and when negative, the subsequent OC did not result in any severe adverse reactions. The BC elicited an isolated late asthmatic response that has not been previously described in the literature.
Collapse
Affiliation(s)
- P Barranco
- Department of Allergology, Hospital Universitario La Paz, Madrid, Spain
| | | | | | | | | | | |
Collapse
|
31
|
Belver MT, Jurado-Palomo J, Bobolea I, López-Serrano MC, Quirce S. Immunoglobulin E reactivity to nOle e 1 as a diagnostic marker of allergy to Olea europaea pollen. J Investig Allergol Clin Immunol 2009; 19:515-516. [PMID: 20128435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Affiliation(s)
- M T Belver
- Hospital Universitario La Paz, Servicio de Alergia, Madrid, Spain, Bilbao, Spain.
| | | | | | | | | |
Collapse
|